Table 1.
Demographic Information and Antibody Profile From 1976 EBOV Zaire Ebola Virus Disease Survivors, Yambuku, Democratic Republic of the Congo (n = 14)
| Demographic Information | Serologic Results | Neutralization Assays (% Neutralization) | Plaque Reduction Neutralization Test (PRNT)f | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Complement | With Complement | ||||||||||||
| Ebola Survivor (ES) | Age at Infection | Current Agea | Sex | CaseClassification | GPb | NPb | VP40c | Pseudo- Virusd | Entry Inhibitione | PRNT (50%) | PRNT (80%) | PRNT (50%) | PRNT (80%) |
| 1 | 26 | 66 | M | Suspected | ~ + | ~ + | − | 27.53% | 32.28% | − | − | − | − |
| 2 | 15 | 55 | F | Suspected | ~ + | ~ + | − | 32.66% | 42.07% | − | − | − | − |
| 3 | 15 | 55 | M | Suspected | ~ + | ~ + | − | 29.26% | 36.03% | − | − | − | − |
| 4 | 28 | 68 | M | Confirmed | + | + | − | 70.14% | 75.82% | 1:30 | − | 1:30 | − |
| 5 | 30 | 70 | F | Confirmed | ~ + | + | − | 50.40% | 49.91% | − | − | − | − |
| 6 | 27 | 67 | M | Confirmed | + | ~ + | − | 17.58% | 23.79% | − | − | − | − |
| 7 | 28 | 68 | M | Suspected | − | ~ + | − | 13.13% | 36.12% | − | − | − | − |
| 8 | 22 | 62 | M | Confirmed | + | + | + | 69.12% | 80.10% | 1:60 | 1:30 | 1:30 | − |
| 9 | 28 | 68 | F | Suspected | + | ~ + | − | 37.38% | 37.89% | − | − | − | − |
| 10 | 33 | 73 | F | Suspected | − | ~ + | − | 41.33% | 51.63% | − | − | − | − |
| 11 | 21 | 61 | M | Suspected | ~ + | ~ + | − | 10.14% | 35.82% | − | − | − | − |
| 12 | 46 | 86 | F | Suspected | ~ + | − | − | 22.77% | 17.98% | 1:120 | − | − | − |
| 13 | 22 | 62 | F | Confirmed | ~ + | + | + | 42.85% | 39.40% | 1:30 | − | − | − |
| 14 | 25 | 65 | M | Confirmed | + | + | + | 41.75% | 36.38% | − | − | − | − |
aCurrent age at time of survey administration, January 2016.
bPatient immunoreactivity to Ebola virus Zaire glycoprotein (GP) and nucleoprotein (NP) recombinant viral proteins, assessed by ELISA. ~ +, indicats a likely reactive survivor.
cPatient immunoreactivity to Ebola virus Zaire viral protein 40 (VP40) antigen, assessed by a luciferase immunoprecipitation assay (LIPS).
dResults from pseudovirus neutralization assays are displayed as percent of neutralization as compared to controls.
eEntry inhibition using Ebola virus Zaire-like particles in a G-Luciferase (GLuc) complementation/neutralization assay, neutralization is displayed as a percent of infection compared to controls.
fPlaque reduction neutralization test (PRNT) using live Ebola virus Zaire under BSL-4 conditions. Displayed are the patient serum dilutions necessary to achieve 50% and 80% neutralization, with and without complement proteins present. All 14 subjects were run on PRNT platform and those that did not reach at least 50 or 80% plaque reduction are indicated by −, survivors harboring protective antibodies that were able to neutralize live EBOV to at least 50% of control are marked in bold font.